{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Leslie", "organization": "", "rank": 1, "lastname": "PICKER"}], "original": "By LESLIE PICKER"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"main": "Editas Medicine and BeiGene Gain in Market Debuts"}, "print_page": null, "keywords": [{"value": "Initial Public Offerings", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Beigene Ltd.", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Editas Medicine Inc", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Genetics and Heredity", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Biotechnology and Bioengineering", "is_major": "N", "rank": "5", "name": "subject"}], "snippet": "The two biotech companies\u2019 initial public offerings are testing the waters after a recent sell-off in biotech.", "source": "The New York Times", "lead_paragraph": "The two biotech companies\u2019 initial public offerings are testing the waters after a recent sell-off in biotech.", "word_count": "379", "pub_date": "2016-02-04T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/02/04/business/dealbook/editas-medicine-and-beigene-gain-in-market-debuts.html", "_id": "56b23fb338f0d82036f0a7aa"}